Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Saved in:
| Title: | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. |
|---|---|
| Authors: | Rudin, Charles M1 rudinc@mskcc.org, Pietanza, M Catherine1, Bauer, Todd M2,3, Ready, Neal4, Morgensztern, Daniel5, Glisson, Bonnie S6, Byers, Lauren A6, Johnson, Melissa L2,3, IIIBurris, Howard A2,3, Robert, Francisco7, Han, Tae H8, Bheddah, Sheila8, Theiss, Noah9, Watson, Sky9, Mathur, Deepan9, Vennapusa, Bharathi9, Zayed, Hany8, Lally, Satwant8, Strickland, Donald K3, Govindan, Ramaswamy5 |
| Source: | Lancet Oncology. Jan2017, Vol. 18 Issue 1, p42-51. 10p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
